GlassScriptPhysician profile
Dashi Bao
NPI 1821353970
$8,216.35
in general payments reported to CMS, 2019-2025
36 companies · $1,282 in 2025
The $1,282 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,264 · 2020: $457 · 2021: $980 · 2022: $1,676 · 2023: $1,385 · 2024: $1,173 · 2025: $1,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,805 · Education: $34.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,805.11 |
| Education | $34.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,502.81 | 2019-2025 | Vemlidy |
| Astrazeneca Pharmaceuticals LP | $520.57 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $498.59 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $456.78 | 2019-2025 | Evenity, Repatha, Prolia |
| Amarin Pharma, INC. | $425.19 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $367.93 | 2021-2023 | Jynarque |
| Lilly USA, LLC | $342.47 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $340.21 | 2019-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $337.48 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $312.49 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $310.04 | 2019-2024 | Xarelto |
| Axsome Therapeutics, INC. | $247.53 | 2023-2024 | Auvelity |
| Merck Sharp & Dohme LLC | $177.51 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Biohaven Pharmaceutical Holding Company LTD. | $150.70 | 2022 | |
| Hologic Sales and Service, LLC | $125.00 | 2019 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dashi Bao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.